不明原因低预后不孕夫妇期待管理对比宫腔内人工授精联合卵巢刺激(EXIUI研究):一项随机对照试验
本研究为多中心随机对照非劣效性试验,纳入不明原因不孕且自然受孕预后差(12个月内<30%)的夫妇,比较6个月期待管理与宫腔内人工授精联合卵巢刺激(IUI-OS)的活产率。因纳入缓慢提前终止,共分配92对至期待管理组、86对至IUI-OS组。期待管理组活产率13%(12/92)低于IUI-OS组33%(28/86),RR 0.40(90%CI 0.24-0.67),绝对风险差-20%(90%CI -30%至-9%),未达到非劣效性。
要点
- 不明原因不孕且自然受孕预后差(12个月内<30%)的夫妇,6个月期待管理活产率低于IUI-OS。
- 期待管理组活产12/92(13%),IUI-OS组28/86(33%),RR 0.40(90%CI 0.24-0.67)。
- 试验因纳入缓慢提前终止,未达到计划样本量1091对。
核心结论
- 在不明原因不孕且自然受孕预后差的夫妇中,6个月期待管理在活产方面劣于IUI-OS。
研究设计与样本
- 非劣效性多中心随机对照试验,在荷兰产科和妇科医疗评估与研究联盟框架内进行。
- 计划3年内纳入1091对夫妇,按1:1分配至6个月期待管理或6个月IUI-OS(使用克罗米芬或促性腺激素)。
- 实际于2016年10月至2020年9月间分配92对至期待管理组、86对至IUI-OS组,因纳入缓慢提前终止。
- 纳入标准为不明原因不孕且自然受孕预后差(12个月内<30%)的异性夫妇。
- 主要结局为持续妊娠导致活产;非劣效性界值为单侧90%风险差CI下限大于-7%(对比IUI-OS后预期活产率30%)。
主要发现
- 期待管理组活产率12/92(13%),IUI-OS组28/86(33%);RR 0.40(90%CI 0.24-0.67)。
- 绝对风险差为-20%(90%CI -30%至-9%)。
- 活产的风险比为0.36(95%CI 0.18-0.70)。
- 符合方案分析中,期待管理组活产8/70(11%),IUI-OS组26/73(36%);RR 0.32(90%CI 0.18-0.59),风险差-24%(90%CI -36%至-13%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验未达到计划样本量,结果受参与者数量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: For couples with unexplained subfertility and a poor prognosis for natural conception, is 6 months expectant management (EM) inferior to IUI with ovarian stimulation (IUI-OS), in terms of live births? SUMMARY ANSWER: In couples with unexplained subfertility and a poor prognosis for natural conception, 6 months of EM is inferior compared to IUI-OS in terms of live births. WHAT IS KNOWN ALREADY: Couples with unexplained subfertility and a poor prognosis are often treated with IUI-OS. In couples with unexplained subfertility and a relatively good prognosis for natural conception (>30% in 12 months), IUI-OS does not increase the live birth rate as compared to 6 months of EM. However, in couples with a poor prognosis for natural conception (<30% in 12 months), the effectiveness of IUI-OS is uncertain. STUDY DESIGN, SIZE, DURATION: We performed a non-inferiority multicentre randomized controlled trial within the infrastructure of the Dutch Consortium for Healthcare Evaluation and Research in Obstetrics and Gynaecology. We intended to include 1091 couples within 3 years. The couples were allocated in a 1:1 ratio to 6 months EM or 6 months IUI-OS with either clomiphene citrate or gonadotrophins. PARTICIPANTS/MATERIALS, SETTING, METHODS: We studied heterosexual couples with unexplained subfertility and a poor prognosis for natural conception (<30% in 12 months). The primary outcome was ongoing pregnancy leading to a live birth. Non-inferiority would be shown if the lower limit of the one-sided 90% risk difference (RD) CI was less than minus 7% compared to an expected live birth rate of 30% following IUI-OS. We calculated RD, relative risks (RRs) with 90% CI and a corresponding hazard rate for live birth over time based on intention-to-treat and per-protocol (PP) analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Between October 2016 and September 2020, we allocated 92 couples to EM and 86 to IUI-OS. The trial was halted pre-maturely owing to slow inclusion. Mean female age was 34 years, median duration of subfertility was 21 months. Couples allocated to EM had a lower live birth rate than couples allocated to IUI-OS (12/92 (13%) in the EM group versus 28/86 (33%) in the IUI-OS group; RR 0.40 90% CI 0.24 to 0.67). This corresponds to an absolute RD of minus 20%; 90% CI: -30% to -9%. The hazard ratio for live birth over time was 0.36 (95% CI 0.18 to 0.70). In the PP analysis, live births rates were 8 of 70 women (11%) in the EM group versus 26 of 73 women (36%) in the IUI-OS group (RR 0.32, 90% CI 0.18 to 0.59; RD -24%, 90% CI -36% to -13%) in line with inferiority of EM. LIMITATIONS, REASONS FOR CAUTION: Our trial did not reach the planned sample size, therefore the results are limited by the number of participants. WIDER IMPLICATIONS OF THE FINDINGS: This study confirms the results of a previous trial that in couples with unexplained subfertility and a poor prognosis for natural conception, EM is inferior to IUI-OS. STUDY FUNDING/COMPETING INTEREST(S): The trial was supported by a grant of the SEENEZ healthcare initiative. The subsidizing parties were The Dutch Organisation for Health Research and Development (ZonMW 837004023, www.zonmw.nl) and the umbrella organization of 10 health insurers in The Netherlands. E.R.G. receives personal fees from Titus Health care outside the submitted work. M.G. declares unrestricted research and educational grants from Guerbet, Merck and Ferring not related to the presented work, paid to their institution VU medical centre. A.B.H. reports receiving travel and speakers fees from Nordic Pharma and Merck and he is member of the Nordic Pharma ANGEL group and of the Safety Monitoring Board of Womed. C.B.L. reports speakers fee from Inmed and Yingming, and his department receives research grants from Ferring, Merck and Guerbet paid to VU medical centre. B.W.J.M. is supported by a NHMRC Investigator grant (GNT1176437) and reports consultancy for ObsEva and Merck. M.v.W. received a grant from the Netherlands Organisation for Health Research and Development ZonMW (80-8520098-91072). F.M. received two grants from the Netherlands Organisation for Health Research and Development ZonMW (NTR 5599 and NTR 6590). The other authors report no competing interest. TRIAL REGISTRATION NUMBER: Dutch Trial register NL5455 (NTR5599). TRIAL REGISTRATION DATE: 18 December 2015. DATE OF FIRST PATIENT’S ENROLMENT: 26 January 2017.
引用
- Wessel JA, Mochtar MH, Besselink DE, et al. Expectant management versus IUI in unexplained subfertility and a poor pregnancy prognosis (EXIUI study): a randomized controlled trial. Hum Reprod. 2022. PMID: 36331493. doi:10.1093/humrep/deac236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。